Low-grade brain tumor diagnosis redefined
A tumor’s DNA composition plays a key role in whether a glioma may transform into a more serious glioblastoma.
Diagnosis & Disease Information
Survival in adult patients with low-grade brain tumors has improved
Outcomes for patients with low-grade gliomas have improved significantly in recent years, according to an analysis of clinical data collected from a US cancer registry over the past decade.
Bevacizumab-induced hypertension is a marker for improved outcomes in recurrent glioblastoma
Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
Targeting a unique receptor promising for glioblastoma multiforme
Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.
Autologous cancer vaccine extends survival in patients with newly diagnosed GBM
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
Optimal dosing for TMZ: 1 hour prior to RT versus bedtime
Is there a difference in dosing (1 hour prior to radiotherapy vs bedtime) with temozolomide plus radiotherapy for glioblastoma multiforme?
Lightwaves improve brain tumor surgery
First-of-its-kind research shows promise for developing a method to clearly identify cancerous tissue during surgery. These findings may potentially improve outcomes for those undergoing surgery to remove glioblastoma multiforme.
Cancer stem cells targeted in malignant brain tumors
Researchers have also created an experimental vaccine to attack immune system targets related to cancer stem cells, the cells from which malignant brain tumors are believed to originate and regenerate.
Personalized vaccine for most lethal type of brain tumor shows promise
Patients with recurrent GBM treated with an experimental vaccine made from the patient’s own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.
Inflammatory protein converts glioblastoma cells into the most aggressive version
A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy.
- Loading...
Loading...
Loading... 
Loading...